Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Martin Robinson, Nicholas J Slevin, Peter Hoskin, Kevin J. Harrington, David L Morgan, Christopher Gaffney
Publikováno v:
Journal of Clinical Oncology. 27:5751-5756
Purpose To evaluate the effect of epoetin alfa on local disease-free survival (DFS), overall survival (OS), and cancer treatment–related anemia and fatigue in patients with head and neck cancer receiving radical radiotherapy with curative intent. P
Autor:
Justin Kopit, Lisa Licitra, Mark Lynch, Joël Guigay, A. Dimitrios Colevas, Jérôme Fayette, Tamara Rordorf, Makoto Tahara, Nabil F. Saba, Lara Carmen Iglesias Docampo, Kevin J. Harrington, Maura L. Gillison, Robert I. Haddad, Stefan Kasper, Naomi Kiyota, Francis P. Worden, George R. Blumenschein, Robert L. Ferris, Caroline Even, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 35:6019-6019
6019 Background: In CheckMate 141, a randomized, phase 3 trial, nivo demonstrated superior overall survival (OS) and better tolerability in patients (pts) with PR R/M SCCHN compared with IC. Pts with SCCHN progressing within 6 mos of platinum in the
Autor:
Maura L. Gillison, Nabil F. Saba, Caroline Even, Peter Brossart, George R. Blumenschein, Lisa Licitra, Joël Guigay, Jérôme Fayette, Jeffrey Russell, Robert I. Haddad, Robert L. Ferris, Kevin J. Harrington, Shanmugasundaram Ramkumar, Jin Zhu, Manish Monga, Makoto Tahara, A. Dimitrios Colevas, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 35:6020-6020
6020 Background: In CheckMate 141, nivo resulted in significantly prolonged overall survival (OS), favorable safety, and stable quality of life vs IC in patients (pts) with platinum-refractory (PR) R/M SCCHN. Cetuximab, a formal trial stratification
Autor:
F. Adab, B. K. Yap, M. S. Rogers, Roger A'Hern, M. Sydenham, Emma Hall, Christopher M. Nutting, S. Jefferies, Kevin J. Harrington, C. Scrase
Publikováno v:
Journal of Clinical Oncology. 27:LBA6006-LBA6006
LBA6006 Background: Xerostomia is the most common late toxicity of RT to the head and neck. IMRT dose distributions reduce the dose delivered to parotid gland. PARSPORT investigated the role of IMRT in reducing xerostomia in patients with head and ne